Skip to main content
    S

    Seres Therapeutics Inc (MCRB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.42
    -0.11 (-4.35%)

    Market Cap: $25.41M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(21/39)
    Avg Surprise
    -364.66%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.00
    Range$-1.34 - $-0.67
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-2.37+57.6%
    60d ago$-2.37+57.6%
    30d ago$-1.64+38.5%
    7d ago$-1.64+38.5%
    Current$-1.00
    Revenue Consensus
    $6M
    Range$200000 - $13M
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.55
    Range$0.71 - $2.40
    2 analysts
    Revenue Consensus
    $7M
    Range$-5029000 - $20M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.55---
    Sep 26EST
    		-$-1.00---
    Jun 26
    Reported Aug 5
    		$-1.50$-2.07+27.54%Beat+33.9%
    Mar 26
    Reported May 5
    		$-2.08$-1.88-10.64%Miss+7.1%
    Dec 25
    Reported Mar 12
    		$-1.76$-1.60-10.00%Miss-1500.0%
    Sep 25
    Reported Nov 5
    		$0.94$0.05+1780.00%Beat+114.2%
    Jun 25
    Reported Aug 6
    		$-2.27$-2.27+0.00%Beat+48.4%
    Mar 25
    Reported May 7
    		$-2.24$1.97-213.71%Miss+58.5%
    Dec 24
    Reported Mar 13
    		$-0.11$-0.20+44.81%Beat+65.6%
    Sep 24
    Reported Nov 13
    		$-6.60$-0.04-16400.00%Miss+10.8%
    Jun 24
    Reported Aug 13
    		$-4.40$-5.91+25.55%Beat-161.1%
    Mar 24
    Reported May 8
    		$-5.40$-7.25+25.52%Beat+52.6%
    Dec 23
    Reported Mar 5
    		$-0.32$-0.50+36.00%Beat+40.7%
    Sep 23
    Reported Nov 2
    		$-7.40$-10.65+30.52%Beat+24.5%
    Jun 23
    Reported Aug 8
    		$7.20$10.97-34.37%Miss+151.4%
    Mar 23
    Reported May 9
    		$-11.40$-10.85-5.07%Miss+6.6%
    Dec 22
    Reported Mar 7
    		$-0.54$-0.46-17.39%Miss-3.8%
    Sep 22
    Reported Nov 2
    		$-9.80$-9.44-3.81%Miss-168.1%
    Jun 22
    Reported Aug 3
    		$-14.00$-12.30-13.82%Miss-32.1%
    Mar 22
    Reported May 4
    		$-12.20$-10.04-21.51%Miss-56.4%
    Dec 21
    Reported Mar 1
    		$-0.52$-0.44-18.18%Miss-126.1%
    Sep 21
    Reported Nov 10
    		$14.40$-3.46+516.18%Beat+300.0%
    Jun 21
    Reported Aug 3
    		$-10.60$-7.63-38.93%Miss-89.3%
    Mar 21
    Reported May 4
    		$-7.80$-6.30-23.81%Miss-2685.7%
    Dec 20
    Reported Mar 2
    		$-0.23$-0.28+17.86%Beat+95.4%
    Sep 20
    Reported Nov 9
    		$-7.20$-5.00-44.00%Miss-56.5%
    Jun 20
    Reported Jul 28
    		$-5.60$-5.16-8.53%Miss-16.7%
    Mar 20
    Reported May 7
    		$-0.28$-0.28+0.00%Beat+97.5%
    Dec 19
    Reported Mar 2
    		$-5.00$-5.27+5.12%Beat-861.5%
    Sep 19
    Reported Nov 5
    		$-4.60$-5.27+12.71%Beat+57.4%
    Jun 19
    Reported Aug 6
    		$-4.80N/A+53.62%Beat+64.7%
    Mar 19
    Reported May 2
    		$-11.13$-9.20-20.98%Miss+19.3%
    Dec 18
    Reported Mar 6
    		$-0.52$-0.50-4.00%Miss+27.8%
    Sep 18
    Reported Nov 8
    		$-10.80$-10.92+1.10%Beat-217.6%
    Jun 18
    Reported Aug 2
    		$-13.60$-14.00+2.86%Beat+1.4%
    Mar 18
    Reported May 9
    		$-13.80$-15.25+9.51%Beat-9.5%
    Dec 17
    Reported Mar 8
    		$-0.72$-0.75+4.00%Beat-14.3%
    Sep 17
    Reported Nov 8
    		$-3.40N/A+65.66%Beat-
    Jun 17
    Reported Aug 3
    		$-13.80$-12.76-8.15%Miss-
    Mar 17
    Reported May 4
    		$-12.60$-13.13+4.04%Beat-
    Dec 16
    Reported Mar 16
    		$-0.63$-0.72+12.50%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.55EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-2101.00%
    ROE-66.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.11xQuick Ratio2.11x
    Trading Statistics
    Beta0.31Avg Volume77.38K
    52-Week High$29.9852-Week Low$2.38

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.73
    SMA 20$3.24
    SMA 50$4.23
    SMA 200$7.90
    EMA 10$2.80
    EMA 20$3.22
    EMA 50$4.11
    EMA 200$7.47

    MACD

    Line: -0.55Signal: -0.52Hist: -0.03

    ADX

    ADX: 48.6+DI: 8.0-DI: 37.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$2.72

    Bollinger Bands

    Upper Band$4.38
    Lower Band$2.10
    %B Position7029%(Upper)
    Band Width0.14

    RSI (14-Day)

    Oversold
    18.8

    Momentum Oscillators

    Stoch %K8.3
    Stoch %D11.6
    Williams %R-97.3
    ROC (10d)-27.8%
    Momentum-0.93
    CCI (20d)-103.7
    MFI (14d)16.2

    Volatility Measures

    ATR (14d)$0.28(11.6%)
    StdDev (20d)0.57
    Hist Vol55.3%(High)

    Volume Flow

    VWAP$2.48
    OBV-9.4M
    AD Line2.4B
    CMF (20d)-0.322

    Volume Metrics

    Avg Vol (20d)78.7K
    Vol Ratio0.5x
    VWMA (20d)$3.13

    Pivot Points

    R3$2.77
    R2$2.72
    R1$2.62
    Pivot Point$2.57
    S1$2.47
    S2$2.42
    S3$2.32

    Advanced Oscillators

    TSI-55.49
    Ultimate Osc32.3
    KST-386.95

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$736,000$358,000$438,000$351,000$0$0$5.96M$0$0$0$-125,951,000$0
    Cost of Revenue$0$0$-13,805,000$0$0$0$5.13M$0$0$0$4.05M$0
    Gross Profit$736,000$358,000$438,000$351,000$0$0$-5,128,000$0$0$0$-125,951,000$0
    Operating Expenses$22.01M$21.27M$19.82M$22.83M$24.88M$27.24M$28.84M$29.17M$28.87M$34.44M$3.52M$44.59M
    R&D$9.14M$13.20M$11.68M$12.62M$12.94M$11.82M$12.84M$16.46M$15.81M$19.49M$1.68M$25.15M
    SG&A$7.06M$8.07M$7.54M$9.48M$10.25M$11.89M$12.46M$12.71M$13.06M$14.94M$7.55M$19.43M
    Operating Income$-21,273,000$-20,907,000$-19,377,000$-22,477,000$-24,881,000$-27,236,000$-28,836,000$-29,170,000$-28,871,000$-34,438,000$-129,467,000$-44,586,000
    Interest Income$181,000$325,000$445,000$618,000$546,000$618,000$437,000$652,000$1.23M$1.65M$1.97M$2.57M
    Interest Expense$0$0$0$0$0$0$0$21.86M$0$618,000$-2,667,000$0
    Income Before Tax$4.58M$-19,913,000$-15,335,000$8.20M$-19,855,000$32.68M$-15,637,000$-51,035,000$-26,196,000$-32,903,000$-124,493,000$-41,015,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$4.58M$-19,913,000$-15,335,000$8.20M$-19,855,000$32.68M$-15,637,000$88.78M$-32,870,000$-40,133,000$-41,248,000$-47,854,000
    EBITDA$5.07M$-19,457,000$-14,826,000$8.63M$-19,342,000$33.14M$-15,607,000$-49,820,000$-25,521,000$-31,909,000$-127,090,000$-41,510,000
    EBIT$4.40M$-20,238,000$-15,780,000$7.59M$-20,401,000$32.06M$-16,692,000$-51,687,000$-27,426,000$-33,933,000$-129,131,000$-43,587,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MCRB

    News

    Seres Therapeutics stock at EUR 2.28, USD 25.2 million market value

    Seres Therapeutics stock was trading at EUR 2.28 at Lang & Schwarz and USD 2.53 on Nasdaq as of October 15, 2026, with a market capitalization of USD 25.2 million. The stock's 52-week range was USD 2.38 to USD 29.98...

    ad-hoc-news.de•10/15/26•Neutral

    Seres Therapeutics to Present Preclinical Data for

    Seres Therapeutics will present preclinical data for SER-428 at IDWeek 2026. SER-428 is an investigational oral liquid live biotherapeutic designed to reduce bloodstream infections in critically ill patients...

    GlobeNewswire•10/15/26•Bullish

    Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

    Seres Therapeutics will present preclinical data for SER-428, an investigational oral liquid live biotherapeutic product...

    GlobeNewswire•10/15/26•Bullish

    A liquid experimental treatment reduced two bacteria up to 1,000-fold in preclinical tests.

    Seres Therapeutics (Nasdaq: MCRB) is set to present preclinical data for its investigational live biotherapeutic SER-428 at IDWeek on October 22, 2026. This liquid formulation...

    Stock Titan•10/15/26•Neutral

    Analysts see USD 17 target for Seres Therapeutics stock

    Analysts are setting a USD 17 target for Seres Therapeutics (MCRB) stock, despite its current trading price of EUR 2.44 and a 52-week range of USD 2.70 to USD 29.98. The target is based on the company's clinical...

    AD HOC NEWS•10/8/26•Somewhat-Bearish

    MCRB Valuation and Fair Value

    P/E
    -0.6x
    Forward P/E
    10.3x
    PEG
    -0.1x
    P/B
    0.7x
    See GNG's fair value

    MCRB Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -2101.0%
    Net margin
    0.0%
    ROE
    -66.6%
    FCF margin
    -2724.1%

    MCRB Competitors

    CompanyTicker
    PetMed Express IncPETS
    Polyrizon Ltd. Ordinary SharesPLRZ
    SRx Health Solutions Inc.SRXH
    Evaxion Biotech ASEVAX
    India Globalization Capital IncIGC
    Shuttle Pharmaceuticals IncSHPH
    Plus Therapeutics IncPSTV
    Immutep Ltd ADRIMMP

    Sector: Healthcare

    MCRB Bull Case vs Bear Case

    Bear case

    • MCRB beat EPS estimates in 37.5% of its last 8 reported quarters.
    • MCRB's quarterly revenue changed -93.4% year over year.

    MCRB Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    231.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.00
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About MCRB

    Does MCRB pay dividends?

    Seres Therapeutics Inc (MCRB) does not currently pay a regular dividend.

    What is MCRB's market cap?

    Seres Therapeutics Inc (MCRB) has a market capitalization of $25.41M with a current stock price of $2.42.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In